Study: Semaglutide users aged 3+ years backwards
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
19 High-Fiber, Gluten-Free Foods to Nourish Your Gut, According to RDs
Fiber, one of the unsung heroes of our diets, is an essential nutrient. But we know that many of us simply don't get enough on our plates. And many of the obvious high-fiber options — especially whole grains — contain gluten, which some people need to avoid. So what foods can help you effortlessly hit your fiber goals while still allowing you to steer clear of gluten? You have a lot of options, says Natalie Rizzo, registered dietitian and TODAY nutrition editor. While you might initially feel like whole wheat and other grains are your best fiber-rich options, Rizzo's mind goes elsewhere. "When you say high fiber, my main thought would not be gluten-containing foods," she says. Her first choices are more along the lines of beans, fruit and cruciferous vegetables. Considering that fiber has impressive benefits for gut health, heart health and blood sugar management, it's worth finding sources of this important nutrient that you enjoy eating on a regular basis. "Obviously, whole grains have tons (of fiber)," Rizzo says, but there are also so many nutritious, high-fiber foods out there that also happen to be naturally gluten-free. Pears 1 medium pear, 6 grams fiber 'Many people like pears because they are sweet and tender, but people don't realize they are also rich in fiber,' Rizzo said previously. A single pear contains 20% of the fiber you need in a day. In fact, Rizzo calls pears her "secret weapon" in reaching her fiber goal every single day. But if pears aren't your thing, keep in mind that apples are also respectably high in fiber — about 4 grams per apple — and there are a ton of sweet and tart varieties to choose from. Raspberries 1 cup of raspberries, 8 grams fiber Rich in antioxidants, vitamin C and fiber, raspberries are a colorful crowd-pleasing berry. Raspberries are so packed with fiber that they're considered the highest whole-food source of this nutrient you can find, registered dietitian Theresa Gentile told previously. That's why Caroline Susie, registered dietitian, often tells clients who are looking for more fiber to reach for raspberries first. 'The easiest thing to do is go buy a ton of raspberries, put them in your fridge, and have half a cup with breakfast and have half a cup as an afternoon snack,' she explained previously. Figs 5 figs, 5 grams fiber With their mildly sweet flavor and rich color, figs are an easy high-fiber addition to yogurt, cottage cheese or salads. Along with fiber, figs are also a good source of vitamins and minerals, including calcium and magnesium. Lentils 1 half-cup cooked lentils, 8 grams fiber Lentils are one of the best sources for both plant-based protein and fiber, making them a true nutrition superstar. A serving of lentils will also provide B vitamins as well as iron, magnesium and potassium. Try boosting the fiber of your meals by adding lentils to salads or stews, or blending them into burgers, Rizzo said. Quinoa 1 half-cup cooked quinoa, 2.5 grams fiber While quinoa isn't as heavy-hitting in the fiber department as lentils are, they're still a great option — especially when topped or mixed with roasted veggies. We often treat quinoa like a grain in the kitchen, but it's technically a type of seed. That's why it comes with additional benefits that are more often found in seeds than grains, particularly vitamin E and essential minerals that are important for bone health. Black Beans 1 half-cup black beans, 8 grams fiber Like lentils, black beans are cost-effective and contain both gut-health fiber and plant-based protein. Black beans also have some unique nutrient benefits compared to other beans. In particular, they provide antioxidants and a good amount of iron, Rizzo added, which is especially helpful for people who don't eat meat. But if black beans aren't your favorite, just pick another bean! All beans are good sources of fiber and plant-based protein, Rizzo says. Chickpeas 1 half-cup canned chickpeas, 6.5 grams fiber An excellent source of plant-based protein, chickpeas are also rich in fiber. They are also notable as a source of resistant starch, a type of carbohydrate that doesn't get digested the same way as other starches and sugars. For those reasons, chickpeas can help you feel fuller for longer and manage blood sugar. Excellent in salads, soups and stews, chickpeas are also the basis of hummus. Dip some veggies in your hummus for a snack that's high in fiber and rich in flavor yet low in calories. Sweet Potato 1 medium sweet potato (with skin), 4 grams fiber On the starchier side of things, both sweet potato and classic white potato contain fiber. And they provide even more if you eat the skin. Sweet potatoes will net you a little more fiber, along with beta-carotene and vitamin C, while white potatoes excel in potassium. Brussels Sprouts 1 half-cup of roasted Brussels sprouts, 3 grams fiber These tiny cabbages are among the higher-fiber vegetables. Brussels sprouts also provide other essential nutrients, like vitamin C, as well as healthy plant compounds that may even have anti-cancer and heart-health benefits. Peas 1 half-cup cooked green peas, 4 grams fiber Green peas are typically considered a vegetable, but they actually have more in common nutritionally with beans and legumes. That's why they're so surprisingly high in both protein and fiber. A serving of green peas also provides vitamin K, vitamin C and folic acid. They also provide antioxidants lutein and zeaxanthin, which have benefits for vision and eye health, dietitians told previously. Carrots 1 cup chopped carrots, 3.5 grams fiber One of the more kid-friendly vegetables, vibrant carrots are also a great source of dietary fiber. You probably already know that carrots are extremely rich in beta-carotene, which our bodies turn into vitamin A. But you may not know that they also provide 10% of your daily vitamin C and a good helping of antioxidants. Artichokes 1 medium cooked artichoke, 7 grams fiber If you're a little intimidated by the idea of tackling an artichoke, it's understandable. This spiky plant doesn't exactly seem inviting. But if you put in the effort to cook artichoke, this vegetable will reward you with 7 grams of fiber along with tons of other nutritional benefits: You'll get magnesium, potassium, folate, vitamin C and plenty of antioxidants. Brown Rice 1 half-cup of brown rice, 1.5 grams fiber If you're still looking for whole grains, brown rice is a natural fit because it's naturally gluten-free. And, while the 1.5 grams of fiber per half-cup serving may not seem like a lot on this list, it is about three times what you'd get in white rice. Plus, brown rice is a necessary part of so many dishes, like a stir fry, which you can further boost with high-fiber vegetables and protein. It also contains B vitamins, magnesium and selenium. Oats 1 half-cup serving of oats, 4 grams fiber Oats are one of the whole grain options with the most fiber — and they're naturally gluten-free. Along with 4 grams of fiber, a half-cup of oats also provides 5 grams of protein, making this food a perfect way to start your day or part of a midday high-protein snack. However, Rizzo notes, keep in mind that oats may be processed in facilities with gluten-containing foods. So, if you need to avoid gluten, opt for oats that are specifically labeled "gluten-free" on the package, she says. Popcorn 1 serving of air-popped popcorn, 3 to 4 grams fiber Both corn and its popped variety are delicious, high-fiber foods. A serving of popcorn (typically around 3.5 cups) provides between 3 and 4 grams of fiber, making it one of the healthier crunchy snack food options. Meanwhile, a cup of sweet corn will net you between 2 and 3 grams. So, however you like to eat your corn, you'll be getting a good helping of gut-healthy fiber. Almonds 1 ounce almonds, 4 grams fiber While almonds are more famous for their protein content, which is an admirable 6 grams per ounce, they're also high in fiber. In the same serving size of almonds, you'll also get 4 grams of fiber along with vitamin E and magnesium. Pistachios 1 ounce pistachios, 3 grams fiber Almonds tend to get most of the fame for fiber and protein, but pistachios are just as impressive. In a 1-ounce serving of pistachios, you'll get 6 grams of protein (the same as almonds) and 3 grams of gut-healthy fiber. Pistachios also contain some unique healthy plant compounds, which contribute to their vibrant green color. Pumpkin Seeds 1 ounce pumpkin seeds, 2 grams fiber These little seeds manage to pack in a whole lot of nutrition. In addition to the 2 grams of fiber per serving, they also contain more than 8 grams of protein and a massive dose of magnesium. Pumpkin seeds are also a good source of zinc and calcium. Chia Seeds 2 tablespoons chia seeds, 10 grams fiber Chia seeds consistently come up as one of the highest-fiber foods out there. The challenge is that it's difficult to actually eat the full serving size of chia seeds in order to get their impressive benefits, registered dietitian Grace Derocha explained previously. You can use a sprinkling of chia seeds to get a boost of fiber in a smoothie, for example. But chia seed pudding takes advantage of their natural swelling mechanism — and is probably the only way to actually get the full serving comfortably, Derocha said. This article was originally published on
Yahoo
24 minutes ago
- Yahoo
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Inovio Pharmaceuticals Inc (NASDAQ:INO) is on track to submit its BLA for INO 3,107 in the second half of 2025, with the goal of file acceptance by year-end. The company has completed the design verification testing of its Selecttra 5 PSP device, a key milestone for regulatory progress. INO 3,107 has been granted breakthrough therapy designation by the FDA, allowing for a rolling submission of the BLA. Clinical data from INO 3,107 has been published in reputable journals, supporting its potential as a preferred treatment for RRP. Inovio Pharmaceuticals Inc (NASDAQ:INO) has significantly reduced its operating expenses by 31% year-over-year, demonstrating fiscal responsibility. Negative Points Inovio Pharmaceuticals Inc (NASDAQ:INO) experienced a decrease in cash equivalents and short-term investments, from $94.1 million at the end of 2024 to $47.5 million by mid-2025. The company anticipates an operational net cash burn of approximately $22 million for the third quarter of 2025. There is uncertainty regarding the potential need for an advisory committee meeting for the BLA submission, which could impact timelines. The company faces competition from other treatments in the RRP space, which could affect market share and enrollment in confirmatory trials. Inovio Pharmaceuticals Inc (NASDAQ:INO) has not provided specific guidance on the size of its commercial organization, which may impact its ability to effectively launch INO 3,107. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with INO. Q: Are you anticipating having an advisory committee meeting for the BLA submission of INO 3,107? A: Dr. Mike Sumner, Chief Medical Officer, stated that based on interactions with the FDA, there has been no indication that an advisory committee meeting will be necessary. The overall risk-benefit data presented does not suggest a requirement for such a meeting, although the final decision rests with the agency. Q: How does the upcoming regulatory decision for a competitor affect Inovio's launch plans for INO 3,107? A: Dr. Jackie Shea, President and CEO, highlighted significant differences between Inovio's program and the competitor's, including trial design and technology. Inovio's focus is on a placebo-controlled confirmatory trial, and the differences in technology and trial design suggest distinct paths for each product. Q: Was there any delay in the DV testing for the Selecttra 5 PSP device, and how does it impact the BLA submission timeline? A: Dr. Jackie Shea confirmed that while the DV testing involved multiple external vendors and was complex, the overall timeline for the BLA submission remains on track for the second half of the year, with file acceptance expected by year-end. Q: What is the strategy for a redosing approach for INO 3,107 based on recent data? A: Dr. Mike Sumner explained that Inovio plans to implement a redosing strategy, likely involving annual dosing, to enhance the clinical effect and maintain the reduction in surgeries for RRP patients. This approach leverages the strengths of their DNA medicine platform. Q: How does Inovio plan to address potential enrollment challenges for the confirmatory trial if a competitor's product is approved? A: Dr. Mike Sumner noted that the trial is designed to recruit 100 patients across 20 sites in the U.S., and despite potential market competition, there remains a sizable population of patients who may not have immediate access to the competitor's product due to insurance coverage and other factors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
31 minutes ago
- Yahoo
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease." BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?- Target type, drug, molecule type, and region. Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market. What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
